Penalizing FDA for Expanding Mifepristone Access 3 - Reproductive Freedom for All

Formerly NARAL Pro-Choice America

Back to Search

Penalizing FDA for Expanding Mifepristone Access 3

Penalizing FDA for Expanding Mifepristone Access. Agriculture, Rural Development, Food and Drug Administration (FDA), and Related Agencies Appropriations Act, 2024. Good (R-VA) amendment to reduce to $1 the salary of the Director of the Division of Risk Management at the FDA as part of ongoing attempts to limit access to mifepristone by targeting trained experts for their scientific and medical decision making. A vote for reproductive freedom was against the amendment.

This measure negatively impacts reproductive freedom.


September 27, 2023

H.R.4368

Voting Record

Name State/Territory Chamber Party District How they voted
yea

Vote for/in favor of

nay

Vote against

Abstained, absent, ineligible, present, resigned or deceased

L

Leader switched vote to preserve right to file a motion to reconsider

S

The speaker exercised their discretion not to vote

Jennifer Wexton
Jennifer Wexton
Virginia House Democratic VA-10 nay
Susan Wild
Susan Wild
Pennsylvania House Democratic PA-07 nay
Roger Williams
Texas House Republican TX-25 yea
Nikema Williams
Nikema Williams
Georgia House Democratic GA-05 nay
Brandon Williams
Brandon Williams
New York House Republican NY-22 yea
Joe Wilson
South Carolina House Republican SC-02 yea
Frederica Wilson
Florida House Democratic FL-24 nay
Rob Wittman
Virginia House Republican VA-01 yea
Steve Womack
Arkansas House Republican AR-03 nay
Rudy Yakym
Rudy Yakym
Indiana House Republican IN-02 yea
Ryan Zinke
Montana House Republican MT-01 yea